Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Interleukin-6"" wg kryterium: Temat


Tytuł :
Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
Autorzy :
Canziani LM; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; Internal Medicine, Humanitas Gavazzeni, Bergamo (BG), Italy.
Trovati S; Internal Medicine, Humanitas Gavazzeni, Bergamo (BG), Italy.
Brunetta E; General Medicine and Nephrology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Testa A; Internal Medicine, Humanitas Gavazzeni, Bergamo (BG), Italy.
De Santis M; Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Bombardieri E; Scientific Direction, Humanitas Gavazzeni, Bergamo (BG), Italy.
Guidelli G; Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Albano G; Anesthesiology and Intensive Care, Humanitas Gavazzeni, Bergamo (BG), Italy.
Folci M; General Medicine and Hepatology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Squadroni M; Medical Oncology, Humanitas Gavazzeni, Bergamo (BG), Italy.
Beretta GD; Medical Oncology, Humanitas Gavazzeni, Bergamo (BG), Italy.
Ciccarelli M; General Medicine and Pulmonology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Castoldi M; Medical Direction, Humanitas Gavazzeni, Bergamo (BG), Italy.
Lleo A; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; General Medicine and Hepatology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Aghemo A; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; General Medicine and Hepatology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Vernile L; Pharmacy, Humanitas Gavazzeni, Bergamo (BG), Italy.
Malesci A; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; General Medicine and Gastroenterology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Omodei P; General Medicine and Gastroenterology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Angelini C; General Medicine and Nephrology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Badalamenti S; General Medicine and Nephrology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Cecconi M; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; Anesthesiology andIntensive Care, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy. Electronic address: .
Cremonesi A; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; Cardiology, Humanitas Gavazzeni, Bergamo (BG), Italy.
Selmi C; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy. Electronic address: .
Pokaż więcej
Corporate Authors :
Humanitas and Gavazzeni / Castelli COVID-19 Task Forces
Źródło :
Journal of autoimmunity [J Autoimmun] 2020 Nov; Vol. 114, pp. 102511. Date of Electronic Publication: 2020 Jul 08.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized/*administration & dosage
Coronavirus Infections/*drug therapy
Pneumonia, Viral/*drug therapy
Receptors, Interleukin-6/*antagonists & inhibitors
Respiratory Distress Syndrome, Adult/*drug therapy
Aged ; Betacoronavirus/immunology ; Case-Control Studies ; Coronavirus Infections/complications ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Female ; Hospital Mortality ; Humans ; Infusions, Intravenous ; Interleukin-6/immunology ; Interleukin-6/metabolism ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Receptors, Interleukin-6/metabolism ; Respiratory Distress Syndrome, Adult/diagnosis ; Respiratory Distress Syndrome, Adult/immunology ; Respiratory Distress Syndrome, Adult/mortality ; Retrospective Studies ; Severity of Illness Index ; Survival Analysis ; Treatment Outcome
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency.
Autorzy :
Werner-Klein M; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. .
Grujovic A; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.; Telexos GmbH, Weilheim, Germany.
Irlbeck C; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Obradović M; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.; Wellmera AG, Basel, Switzerland.
Hoffmann M; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Koerkel-Qu H; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Lu X; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Treitschke S; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Köstler C; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Botteron C; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Weidele K; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Werno C; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Polzer B; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Kirsch S; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Gužvić M; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Warfsmann J; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Honarnejad K; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Czyz Z; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Feliciello G; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Blochberger I; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Grunewald S; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Schneider E; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Haunschild G; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Patwary N; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Guetter S; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Huber S; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Rack B; Department OB&GYN and CCCLMU, Breast Center, LMU University Hospital, 80337, Munich, Germany.; Department of Gynecology, Ulm University Hospital, Ulm, Germany.
Harbeck N; Department OB&GYN and CCCLMU, Breast Center, LMU University Hospital, 80337, Munich, Germany.
Buchholz S; Clinic of Gynecology and Obstetrics, University Medical Center Regensburg, 93053, Regensburg, Germany.
Rümmele P; Department of Pathology, University of Regensburg, 93053, Regensburg, Germany.; Institute of Pathology, University Hospital, Friedrich-Alexander-University Erlangen-Nürnberg, 91054, Erlangen, Germany.
Heine N; University Center of Plastic-, Aesthetic, Hand- and Reconstructive Surgery, University of Regensburg, Regensburg, Germany.
Rose-John S; Institute of Biochemistry, Christian-Albrechts-Universität Kiel, Kiel, Germany.
Klein CA; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. .; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2020 Oct 05; Vol. 11 (1), pp. 4977. Date of Electronic Publication: 2020 Oct 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Signal Transduction*
Interleukin-6/*metabolism
Neoplastic Stem Cells/*metabolism
Neoplastic Stem Cells/*pathology
Bone Marrow/pathology ; Breast/cytology ; Breast Neoplasms/pathology ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Cytokine Receptor gp130/metabolism ; Epithelial Cells/metabolism ; Epithelial Cells/pathology ; Female ; Humans ; Interleukin-6/genetics ; Mutation ; Neoplasm Metastasis/genetics ; Receptors, Interleukin-6/deficiency ; Receptors, Interleukin-6/metabolism ; Stromal Cells/metabolism ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Autorzy :
Kang S; Department of Immune Regulation, Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan.
Tanaka T; Medical Affairs Bureau, Osaka Habikino Medical Center, Osaka 583-8588, Japan.
Inoue H; Department of Immune Regulation, Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan.
Ono C; Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.
Hashimoto S; Department of Clinical Laboratory, Osaka Habikino Medical Center, Osaka 583-8588, Japan.
Kioi Y; Department of Immune Regulation, Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan.
Matsumoto H; Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Matsuura H; Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Matsubara T; Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Shimizu K; Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Ogura H; Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Matsuura Y; Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.
Kishimoto T; Department of Immune Regulation, Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan; .
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2020 Sep 08; Vol. 117 (36), pp. 22351-22356. Date of Electronic Publication: 2020 Aug 21.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Signal Transduction*
Cytokine Release Syndrome/*metabolism
Endothelial Cells/*metabolism
Interleukin-6/*metabolism
Plasminogen Activator Inhibitor 1/*metabolism
Adult ; Aged ; Antibodies, Monoclonal, Humanized/therapeutic use ; Betacoronavirus ; Burns/metabolism ; Burns/pathology ; Cells, Cultured ; Coronavirus Infections/drug therapy ; Coronavirus Infections/metabolism ; Coronavirus Infections/pathology ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/pathology ; Cytokines/blood ; Cytokines/metabolism ; Endothelial Cells/drug effects ; Female ; Humans ; Inflammation ; Interleukin-6/blood ; Male ; Middle Aged ; Pandemics ; Plasminogen Activator Inhibitor 1/blood ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/metabolism ; Pneumonia, Viral/pathology ; Receptors, Interleukin-6/antagonists & inhibitors ; Receptors, Interleukin-6/metabolism ; Respiratory Distress Syndrome, Adult/metabolism ; Respiratory Distress Syndrome, Adult/pathology ; Sepsis/metabolism ; Sepsis/pathology
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Preemptive interleukin-6 blockade in patients with COVID-19.
Autorzy :
Guillén L; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Padilla S; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Fernández M; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Agulló V; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
García JA; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Telenti G; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
García-Abellán J; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Botella Á; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Gutiérrez F; Clinical Medicine Department, Universidad Miguel Hernández, Ctra. de Valencia (N-322), Km 87, 03550, San Juan de Alicante, Spain. .; Universidad Miguel Hernández, Avda de la Universidad S/N, Elche, 03202, Alicante, Spain. .
Masiá M; Clinical Medicine Department, Universidad Miguel Hernández, Ctra. de Valencia (N-322), Km 87, 03550, San Juan de Alicante, Spain. .; Universidad Miguel Hernández, Avda de la Universidad S/N, Elche, 03202, Alicante, Spain. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 08; Vol. 10 (1), pp. 16826. Date of Electronic Publication: 2020 Oct 08.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Betacoronavirus*
Organ Dysfunction Scores*
Antibodies, Monoclonal, Humanized/*pharmacology
Antibodies, Monoclonal, Humanized/*therapeutic use
Coronavirus Infections/*drug therapy
Pneumonia, Viral/*drug therapy
Receptors, Interleukin-6/*antagonists & inhibitors
Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Biomarkers/blood ; C-Reactive Protein/analysis ; Coronavirus Infections/epidemiology ; Coronavirus Infections/virology ; Female ; Follow-Up Studies ; Humans ; Interleukin-6/blood ; Lymphocyte Count ; Lymphocytes ; Male ; Middle Aged ; Neutrophils ; Pandemics ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/virology ; Spain/epidemiology ; Treatment Outcome
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.
Autorzy :
Della-Torre E; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy .; Università Vita-Salute San Raffaele, Milan, Italy.
Campochiaro C; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy.; Università Vita-Salute San Raffaele, Milan, Italy.
Cavalli G; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy.; Università Vita-Salute San Raffaele, Milan, Italy.
De Luca G; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy.; Università Vita-Salute San Raffaele, Milan, Italy.
Napolitano A; Università Vita-Salute San Raffaele, Milan, Italy.; Clinical and Experimental Radiology Unit, Experimental Imaging Center, San Raffaele Hospital, Milan, Italy.
La Marca S; Università Vita-Salute San Raffaele, Milan, Italy.; Clinical and Experimental Radiology Unit, Experimental Imaging Center, San Raffaele Hospital, Milan, Italy.
Boffini N; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy.
Da Prat V; General Medicine and Advanced Care Unit, San Raffaele Hospital, Milan, Italy.
Di Terlizzi G; General Medicine and Advanced Care Unit, San Raffaele Hospital, Milan, Italy.
Lanzillotta M; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy.; Università Vita-Salute San Raffaele, Milan, Italy.
Rovere Querini P; Università Vita-Salute San Raffaele, Milan, Italy.; Internal Medicine, Diabetes & Endocrinology Unit, San Raffaele Hospital, Milan, Italy.
Ruggeri A; Hematology and Bone Marrow Transplant Unit, San Raffaele Hospital, Milan, Italy.
Landoni G; Università Vita-Salute San Raffaele, Milan, Italy.; Department of Anesthesia and Intensive Care, San Raffaele Hospital, Milan, Italy.
Tresoldi M; General Medicine and Advanced Care Unit, San Raffaele Hospital, Milan, Italy.
Ciceri F; Università Vita-Salute San Raffaele, Milan, Italy.; Hematology and Bone Marrow Transplant Unit, San Raffaele Hospital, Milan, Italy.
Zangrillo A; Università Vita-Salute San Raffaele, Milan, Italy.; Department of Anesthesia and Intensive Care, San Raffaele Hospital, Milan, Italy.
De Cobelli F; Università Vita-Salute San Raffaele, Milan, Italy.; Clinical and Experimental Radiology Unit, Experimental Imaging Center, San Raffaele Hospital, Milan, Italy.
Dagna L; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy .; Università Vita-Salute San Raffaele, Milan, Italy.
Pokaż więcej
Corporate Authors :
SARI-RAF Study Group
SARI-RAF Study Group members
Źródło :
Annals of the rheumatic diseases [Ann Rheum Dis] 2020 Oct; Vol. 79 (10), pp. 1277-1285. Date of Electronic Publication: 2020 Jul 03.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
C-Reactive Protein/*immunology
Coronavirus Infections/*drug therapy
Inflammation/*immunology
Interleukin-6/*immunology
Pneumonia, Viral/*drug therapy
Administration, Intravenous ; Anti-Bacterial Agents/therapeutic use ; Antiviral Agents/therapeutic use ; Azithromycin/therapeutic use ; Bacteremia/epidemiology ; Betacoronavirus ; Cohort Studies ; Coinfection/epidemiology ; Coronavirus Infections/diagnostic imaging ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Drug Combinations ; Enzyme Inhibitors/therapeutic use ; Female ; Humans ; Hydroxychloroquine/therapeutic use ; Italy ; Lopinavir/therapeutic use ; Lung/diagnostic imaging ; Male ; Middle Aged ; Noninvasive Ventilation ; Oxygen Inhalation Therapy ; Pandemics ; Pneumonia, Viral/diagnostic imaging ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Proportional Hazards Models ; Receptors, Interleukin-6/antagonists & inhibitors ; Ritonavir/therapeutic use ; Severity of Illness Index ; Time Factors ; Tomography, X-Ray Computed ; Treatment Outcome
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.
Autorzy :
Mojtabavi H; Universal Scientific Education and Research Network (USERN), Systematic Review and Meta-Analysis Expert Group (SRMEG), Tehran, Iran, Tehran University of Medical Sciences, Children's Medical Center, Research Center for Immunodeficiencies, Tehran, Iran.
Saghazadeh A; Universal Scientific Education and Research Network (USERN), Systematic Review and Meta-Analysis Expert Group (SRMEG), Tehran, Iran, Tehran University of Medical Sciences, Children's Medical Center, Research Center for Immunodeficiencies, Tehran, Iran.
Rezaei N; Tehran University of Medical Sciences, Children's Medical Center, Research Center for Immunodeficiencies, Tehran, Iran, Tehran University of Medical Sciences, School of Medicine, Department of Immunology, Tehran, Iran, Universal Scientific Education and Research Network (USERN), Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Tehran, Iran.
Pokaż więcej
Źródło :
European cytokine network [Eur Cytokine Netw] 2020 Jun 01; Vol. 31 (2), pp. 44-49.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Anti-Inflammatory Agents/*therapeutic use
Antibodies, Monoclonal, Humanized/*administration & dosage
Antiviral Agents/*therapeutic use
Betacoronavirus/*immunology
Coronavirus Infections/*drug therapy
Cytokine Release Syndrome/*drug therapy
Interleukin-6/*antagonists & inhibitors
Pneumonia, Viral/*drug therapy
Aged ; Betacoronavirus/pathogenicity ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Coronavirus Infections/virology ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/mortality ; Cytokine Release Syndrome/virology ; Female ; Gene Expression ; Humans ; Intensive Care Units ; Interleukin-6/genetics ; Interleukin-6/immunology ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Pneumonia, Viral/virology ; Receptors, Interleukin-6/genetics ; Receptors, Interleukin-6/immunology ; Severity of Illness Index ; Survival Analysis ; Treatment Outcome
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
Autorzy :
Smetana K Jr; Institute of Anatomy, First Faculty of Medicine, Charles University, Prague, Czech Republic .; BIOCEV, Vestec, Czech Republic.
Brábek J; BIOCEV, Vestec, Czech Republic .; Department of Cell Biology, Faculty of Sciences, Charles University, Prague, Czech Republic.
Pokaż więcej
Źródło :
In vivo (Athens, Greece) [In Vivo] 2020 Jun; Vol. 34 (3 Suppl), pp. 1589-1592.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Coronavirus Infections/*complications
Cytokine Release Syndrome/*etiology
Interleukin-6/*physiology
Pneumonia, Viral/*complications
Anti-Inflammatory Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antiviral Agents/therapeutic use ; Clinical Trials as Topic ; Coronavirus Infections/drug therapy ; Coronavirus Infections/immunology ; Coronavirus Infections/physiopathology ; Cytokine Receptor gp130/antagonists & inhibitors ; Cytokine Receptor gp130/physiology ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/physiopathology ; Humans ; Immunotherapy ; Indoles/therapeutic use ; Interleukin-6/antagonists & inhibitors ; Lung/pathology ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/immunology ; Pneumonia, Viral/physiopathology ; Receptors, Interleukin-6/antagonists & inhibitors ; Receptors, Interleukin-6/physiology ; Receptors, Virus/drug effects ; Signal Transduction
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.
Autorzy :
Montesarchio V; Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.
Parrela R; Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.
Iommelli C; Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.
Bianco A; Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.
Manzillo E; Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.
Fraganza F; Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
Palumbo C; Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
Rea G; Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
Murino P; Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
De Rosa R; Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
Atripaldi L; Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
D'Abbraccio M; Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.
Curvietto M; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Mallardo D; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Celentano E; Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Grimaldi AM; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Palla M; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Trojaniello C; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Vitale MG; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Million-Weaver SL; Independent Investigator, Madison, Wisconsin, USA.
Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy .
Pokaż więcej
Źródło :
Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Aug; Vol. 8 (2).
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Biomarkers, Pharmacological/*blood
Coronavirus Infections/*drug therapy
Interleukin-6/*blood
Pneumonia, Viral/*drug therapy
Aged ; Antiviral Agents/therapeutic use ; Coronavirus Infections/complications ; Coronavirus Infections/diagnostic imaging ; Female ; Humans ; Italy ; Lymphocyte Count ; Male ; Middle Aged ; Neutrophils ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/diagnostic imaging ; Receptors, Interleukin-6/antagonists & inhibitors ; Retrospective Studies ; Treatment Outcome
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Autorzy :
Saha A; Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal, India.
Sharma AR; Institute for Skeletal Aging and Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, Gangwon-do, South Korea.
Bhattacharya M; Department of Zoology, Fakir Mohan University, Balasore, Odisha, India.
Sharma G; Neuropsychopharmacology and Toxicology Program, College of Pharmacy, Kangwon National University, Gangwon-do, South Korea.
Lee SS; Institute for Skeletal Aging and Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, Gangwon-do, South Korea.
Chakraborty C; Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal, India. Electronic address: .
Pokaż więcej
Źródło :
Archives of medical research [Arch Med Res] 2020 Aug; Vol. 51 (6), pp. 595-597. Date of Electronic Publication: 2020 May 21.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Coronavirus Infections/*drug therapy
Cytokine Release Syndrome/*drug therapy
Pneumonia, Viral/*drug therapy
Receptors, Interleukin-6/*antagonists & inhibitors
Betacoronavirus ; Humans ; Interleukin-6/immunology ; Pandemics ; Protein Binding ; Signal Transduction
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.
Autorzy :
Crisafulli S; Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Policlinico Universitario 'G. Martino', Via Consolare Valeria 1, 98125, Messina, Italy.
Isgrò V; Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Policlinico Universitario 'G. Martino', Via Consolare Valeria 1, 98125, Messina, Italy.
La Corte L; Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina, Italy.
Atzeni F; Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina, Italy.
Trifirò G; Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Policlinico Universitario 'G. Martino', Via Consolare Valeria 1, 98125, Messina, Italy. .
Pokaż więcej
Źródło :
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2020 Aug; Vol. 34 (4), pp. 415-422.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Coronavirus Infections/*therapy
Interleukin-6/*antagonists & inhibitors
Pneumonia, Viral/*therapy
Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Coronavirus Infections/metabolism ; Coronavirus Infections/pathology ; Humans ; Pandemics ; Pneumonia, Viral/metabolism ; Pneumonia, Viral/pathology ; Receptors, Interleukin-6/antagonists & inhibitors ; Risk Assessment ; Safety
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart.
Autorzy :
Perricone C; Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
Conigliaro P; Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Ciccacci C; UniCamillus, Saint Camillus International University of Health Sciences, Rome, and Department of Biomedicine and Prevention, Section of Genetics, School of Medicine, University of Rome Tor Vergata, Rome, Italy.
Marcucci E; Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
Cafaro G; Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
Bartoloni E; Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
Perricone R; Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Novelli G; Department of Biomedicine and Prevention, Section of Genetics, School of Medicine, University of Rome Tor Vergata, Rome, Italy.
Borgiani P; Department of Biomedicine and Prevention, Section of Genetics, School of Medicine, University of Rome Tor Vergata, Rome, Italy.
Gerli R; Rheumatology Unit, Department of Medicine, University of Perugia, Italy. .
Pokaż więcej
Źródło :
Clinical and experimental rheumatology [Clin Exp Rheumatol] 2020 May-Jun; Vol. 38 (3), pp. 580. Date of Electronic Publication: 2020 May 10.
Typ publikacji :
Letter
MeSH Terms :
Adaptor Proteins, Signal Transducing/*genetics
Coronavirus Infections/*drug therapy
Coronavirus Infections/*genetics
Interleukin-6/*antagonists & inhibitors
Pneumonia, Viral/*drug therapy
Pneumonia, Viral/*genetics
Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antigens, CD/genetics ; Antigens, Differentiation, T-Lymphocyte/genetics ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/genetics ; Betacoronavirus ; Humans ; Lectins, C-Type/genetics ; Middle Aged ; Pandemics ; Polymorphism, Single Nucleotide ; Receptors, Interleukin-6/genetics
SCR Disease Name :
COVID-19
Opinia redakcyjna
Tytuł :
Clinical benefits of Tocilizumab in COVID-19-related cytokine release syndrome in a patient with end-stage kidney disease on haemodialysis in Australia.
Autorzy :
Stephen S; Department of General Medicine, Epworth Richmond Hospital, Richmond, Victoria, Australia.; Department of General Medicine, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Park YA; Department of General Medicine, Epworth Richmond Hospital, Richmond, Victoria, Australia.; Department of General Medicine, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Chrysostomou A; Department of General Medicine, Epworth Richmond Hospital, Richmond, Victoria, Australia.; Department of Renal Medicine, Epworth Richmond Hospital, Richmond, Victoria, Australia.; The University of Melbourne, Parkville, Victoria, Australia.
Pokaż więcej
Źródło :
Nephrology (Carlton, Vic.) [Nephrology (Carlton)] 2020 Nov; Vol. 25 (11), pp. 845-849. Date of Electronic Publication: 2020 Sep 17.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Anemia*/etiology
Anemia*/therapy
Coronavirus Infections*/complications
Coronavirus Infections*/diagnosis
Coronavirus Infections*/immunology
Coronavirus Infections*/therapy
Cytokine Release Syndrome*/blood
Cytokine Release Syndrome*/therapy
Cytokine Release Syndrome*/virology
Interleukin-6*/antagonists & inhibitors
Interleukin-6*/blood
Kidney Failure, Chronic*/complications
Kidney Failure, Chronic*/therapy
Pandemics*
Pneumonia, Viral*/complications
Pneumonia, Viral*/diagnosis
Pneumonia, Viral*/immunology
Pneumonia, Viral*/therapy
Antibodies, Monoclonal, Humanized/*administration & dosage
Aged ; Blood Transfusion/methods ; C-Reactive Protein/analysis ; Female ; Humans ; Immunologic Factors/administration & dosage ; Monitoring, Immunologic/methods ; Renal Dialysis/methods ; Respiration, Artificial/methods ; Treatment Outcome
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics.
Autorzy :
Abbasifard M; Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; Department of Internal Medicine, Ali-Ibn-Abi-talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Khorramdelazad H; Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2020 Sep 15; Vol. 257, pp. 118097. Date of Electronic Publication: 2020 Jul 15.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Betacoronavirus/*immunology
Coronavirus Infections/*immunology
Interleukin-6/*immunology
Pneumonia, Viral/*immunology
Betacoronavirus/metabolism ; Coronavirus Infections/metabolism ; Cytokines/immunology ; Humans ; Inflammation/immunology ; Interleukin-6/metabolism ; Interleukin-6/pharmacology ; Middle East Respiratory Syndrome Coronavirus/immunology ; Pandemics ; Pneumonia, Viral/metabolism ; SARS Virus/immunology
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.
Autorzy :
Tholin B; Department of Internal Medicine, Molde Hospital, Molde, Norway. .
Hauge MT; Department of Internal Medicine, Molde Hospital, Molde, Norway.; Department of Microbiology, Molde Hospital, Molde, Norway.
Aukrust P; Research Institute of Internal Medicine, Oslo University Hospital and University of Oslo, Oslo, Norway.; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.
Fehrle L; Department of Anesthesiology, Molde Hospital, Molde, Norway.
Tvedt TH; Section of Hematology, Department of Internal Medicine, Haukeland University Hospital, Bergen, Norway.
Pokaż więcej
Źródło :
Journal of medical case reports [J Med Case Rep] 2020 Oct 15; Vol. 14 (1), pp. 187. Date of Electronic Publication: 2020 Oct 15.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Coronavirus Infections*/blood
Coronavirus Infections*/complications
Coronavirus Infections*/diagnosis
Coronavirus Infections*/therapy
Interleukin-6*/analysis
Interleukin-6*/antagonists & inhibitors
Pandemics*
Pneumonia, Viral*/blood
Pneumonia, Viral*/complications
Pneumonia, Viral*/diagnosis
Pneumonia, Viral*/therapy
Antibodies, Monoclonal, Humanized/*administration & dosage
Betacoronavirus/*isolation & purification
Inflammation/*blood
Aged ; Antibodies, Monoclonal/administration & dosage ; C-Reactive Protein/analysis ; Ferritins/blood ; Humans ; Lymphohistiocytosis, Hemophagocytic/etiology ; Male ; Respiration, Artificial/methods ; Treatment Outcome
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Effect of NMO-IgG on the interleukin-6 cascade in astrocytes via activation of the JAK/STAT3 signaling pathway.
Autorzy :
Du L; Department of Neurology, Beijing Tiantan Hospital; China National Clinical Research Center for Neurological Diseases; Advanced Innovation Center for Human Brain Protection, Beijing Institute of Brain Disorders, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing 100070, China.
Chang H; Department of Neurology, Beijing Tiantan Hospital; China National Clinical Research Center for Neurological Diseases; Advanced Innovation Center for Human Brain Protection, Beijing Institute of Brain Disorders, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing 100070, China.
Xu W; Department of Neurology, Beijing Tiantan Hospital; China National Clinical Research Center for Neurological Diseases; Advanced Innovation Center for Human Brain Protection, Beijing Institute of Brain Disorders, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing 100070, China.
Wei Y; Department of Neurology, Beijing Tiantan Hospital; China National Clinical Research Center for Neurological Diseases; Advanced Innovation Center for Human Brain Protection, Beijing Institute of Brain Disorders, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing 100070, China.
Wang Y; Department of Neurology, Beijing Tiantan Hospital; China National Clinical Research Center for Neurological Diseases; Advanced Innovation Center for Human Brain Protection, Beijing Institute of Brain Disorders, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing 100070, China.
Yin L; Department of Neurology, Beijing Tiantan Hospital; China National Clinical Research Center for Neurological Diseases; Advanced Innovation Center for Human Brain Protection, Beijing Institute of Brain Disorders, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing 100070, China. Electronic address: .
Zhang X; Department of Neurology, Beijing Tiantan Hospital; China National Clinical Research Center for Neurological Diseases; Advanced Innovation Center for Human Brain Protection, Beijing Institute of Brain Disorders, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing 100070, China. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2020 Oct 01; Vol. 258, pp. 118217. Date of Electronic Publication: 2020 Aug 06.
Typ publikacji :
Journal Article
MeSH Terms :
Astrocytes/*metabolism
Immunoglobulin G/*blood
Interleukin-6/*metabolism
Janus Kinases/*metabolism
Neuromyelitis Optica/*blood
STAT3 Transcription Factor/*metabolism
Adult ; Aged ; Animals ; Astrocytes/drug effects ; Autoantibodies/blood ; Autoantibodies/pharmacology ; Cells, Cultured ; Female ; Humans ; Immunoglobulin G/pharmacology ; Interleukin-6/agonists ; Male ; Middle Aged ; Rats ; Rats, Wistar ; STAT3 Transcription Factor/agonists ; Signal Transduction/drug effects ; Signal Transduction/physiology ; Young Adult
Czasopismo naukowe
Tytuł :
Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation.
Autorzy :
Paniri A; Student Research Committee, Babol University of Medical Sciences, Babol, Iran; Genetics Department, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.
Akhavan-Niaki H; Genetics Department, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran; Zoonoses Research Center, Pasteur Institute of Iran, Amol, Iran. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2020 Sep 15; Vol. 257, pp. 118114. Date of Electronic Publication: 2020 Jul 18.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Betacoronavirus/*genetics
Coronavirus Infections/*immunology
Interleukin-6/*immunology
Pneumonia, Viral/*immunology
RNA, Long Noncoding/*physiology
Anti-Inflammatory Agents/pharmacology ; Betacoronavirus/immunology ; Betacoronavirus/metabolism ; Coronavirus Infections/metabolism ; Cytokines/genetics ; Cytokines/immunology ; Humans ; Inflammasomes/immunology ; Inflammation/immunology ; Interleukin-6/metabolism ; Interleukin-6/pharmacology ; NLR Family, Pyrin Domain-Containing 3 Protein/immunology ; Pandemics ; Pneumonia, Viral/metabolism ; RNA, Long Noncoding/genetics
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Taste and Smell Disorders in COVID-19 Patients: Role of Interleukin-6.
Autorzy :
Cazzolla AP; Department of Clinical and Experimental Medicine, Università degli Studi di Foggia, Foggia 71122, Italy.
Lovero R; AOU Policlinico Consorziale di Bari - Ospedale Giovanni XXIII, Clinical Pathology Unit, Bari 70124, Italy.
Lo Muzio L; Department of Clinical and Experimental Medicine, Università degli Studi di Foggia, Foggia 71122, Italy.
Testa NF; Department of Clinical and Experimental Medicine, Università degli Studi di Foggia, Foggia 71122, Italy.
Schirinzi A; AOU Policlinico Consorziale di Bari - Ospedale Giovanni XXIII, Clinical Pathology Unit, Bari 70124, Italy.
Palmieri G; Private practice, Bari 70124, Italy.
Pozzessere P; AOU Policlinico Consorziale di Bari - Ospedale Giovanni XXIII, Emergency Medicine and Surgery Unit, Bari 70124, Italy.
Procacci V; AOU Policlinico Consorziale di Bari - Ospedale Giovanni XXIII, Emergency Medicine and Surgery Unit, Bari 70124, Italy.
Di Comite M; Department of Basic Medical Sciences, Neurosciences and Sensory Organs, Human Anatomy Section, Università degli Studi di Bari, Bari 70124, Italy.
Ciavarella D; Department of Clinical and Experimental Medicine, Università degli Studi di Foggia, Foggia 71122, Italy.
Pepe M; AOU Policlinico Consorziale di Bari - Ospedale Giovanni XXIII, Clinical Pathology Unit, Bari 70124, Italy.
De Ruvo C; Maugeri Clinical Research Institutes IRCCS of Bari, Bari 70124, Italy.
Crincoli V; Department of Basic Medical Sciences, Neurosciences and Sensory Organs, Human Anatomy Section, Università degli Studi di Bari, Bari 70124, Italy.
Di Serio F; AOU Policlinico Consorziale di Bari - Ospedale Giovanni XXIII, Clinical Pathology Unit, Bari 70124, Italy.
Santacroce L; Ionian Department (DJSGEM), Microbiology and Virology Lab, Università degli Studi di Bari, Bari 70124, Italy.
Pokaż więcej
Źródło :
ACS chemical neuroscience [ACS Chem Neurosci] 2020 Sep 02; Vol. 11 (17), pp. 2774-2781. Date of Electronic Publication: 2020 Aug 19.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Betacoronavirus*
Coronavirus Infections/*blood
Interleukin-6/*blood
Olfaction Disorders/*blood
Pneumonia, Viral/*blood
Taste Disorders/*blood
Aged ; Aged, 80 and over ; Biomarkers/blood ; Coronavirus Infections/complications ; Coronavirus Infections/diagnosis ; Female ; Health Surveys/methods ; Humans ; Interleukin-6/physiology ; Male ; Middle Aged ; Olfaction Disorders/diagnosis ; Olfaction Disorders/etiology ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/diagnosis ; Taste/physiology ; Taste Disorders/diagnosis ; Taste Disorders/etiology
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Changes in the cerebrospinal fluid lipid profile following subarachnoid hemorrhage in a closed cranium model: Correlations to cerebral vasospasm, neuronal cell death and Interleukin-6 synthesis. A pilot study.
Autorzy :
Croci D; Cerebrovascular Research Group, Department of BioMedical Research, University of Bern, Switzerland; Department of Neurosurgery, Neurocenter of Southern Switzerland, Regional Hospital Lugano, Switzerland. Electronic address: .
Nevzati E; Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland; Cerebrovascular Research Group, Department of BioMedical Research, University of Bern, Switzerland; Department of Neurosurgery, Kantonsspital Luzern, Lucerne, Switzerland. Electronic address: .
Muroi C; Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland.
Schöpf S; Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland. Electronic address: .
Hornemann T; Institute of Clinical Chemistry, University and University Hospital Zurich, Switzerland. Electronic address: .
Widmer HR; Department of Neurosurgery, Bern University Hospital, Inselspital Bern, Switzerland. Electronic address: .
Danura H; Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland; Cerebrovascular Research Group, Department of BioMedical Research, University of Bern, Switzerland. Electronic address: .
Fandino J; Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland; Cerebrovascular Research Group, Department of BioMedical Research, University of Bern, Switzerland. Electronic address: .
Marbacher S; Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland; Cerebrovascular Research Group, Department of BioMedical Research, University of Bern, Switzerland. Electronic address: .
Pokaż więcej
Źródło :
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association [J Stroke Cerebrovasc Dis] 2020 Sep; Vol. 29 (9), pp. 105054. Date of Electronic Publication: 2020 Jun 23.
Typ publikacji :
Journal Article
MeSH Terms :
Vasoconstriction*
Basilar Artery/*physiopathology
Interleukin-6/*cerebrospinal fluid
Lipids/*cerebrospinal fluid
Neurons/*metabolism
Subarachnoid Hemorrhage/*cerebrospinal fluid
Vasospasm, Intracranial/*cerebrospinal fluid
Animals ; Apoptosis ; Basilar Artery/diagnostic imaging ; Biomarkers/cerebrospinal fluid ; Disease Models, Animal ; Interleukin-6/biosynthesis ; Intracranial Pressure ; Neurons/pathology ; Phosphatidylcholines/cerebrospinal fluid ; Phosphatidylethanolamines/cerebrospinal fluid ; Pilot Projects ; Rabbits ; Subarachnoid Hemorrhage/diagnostic imaging ; Subarachnoid Hemorrhage/pathology ; Subarachnoid Hemorrhage/physiopathology ; Vasospasm, Intracranial/diagnostic imaging ; Vasospasm, Intracranial/pathology ; Vasospasm, Intracranial/physiopathology
Czasopismo naukowe
Tytuł :
Is a "Cytokine Storm" Relevant to COVID-19?
Autorzy :
Sinha P; Division of Pulmonary, Department of Medicine, Critical Care, Allergy and Sleep Medicine; University of California, San Francisco.; Department of Anesthesia; University of California, San Francisco.
Matthay MA; Division of Pulmonary, Department of Medicine, Critical Care, Allergy and Sleep Medicine; University of California, San Francisco.; Department of Anesthesia; University of California, San Francisco.; Cardiovascular Research Institute; University of California, San Francisco.
Calfee CS; Division of Pulmonary, Department of Medicine, Critical Care, Allergy and Sleep Medicine; University of California, San Francisco.; Department of Anesthesia; University of California, San Francisco.; Cardiovascular Research Institute; University of California, San Francisco.
Pokaż więcej
Źródło :
JAMA internal medicine [JAMA Intern Med] 2020 Sep 01; Vol. 180 (9), pp. 1152-1154.
Typ publikacji :
Editorial; Research Support, N.I.H., Extramural
MeSH Terms :
Coronavirus Infections*/complications
Coronavirus Infections*/immunology
Coronavirus Infections*/physiopathology
Cytokine Release Syndrome*/diagnosis
Cytokine Release Syndrome*/immunology
Cytokine Release Syndrome*/therapy
Interleukin-6*/analysis
Interleukin-6*/antagonists & inhibitors
Interleukin-6*/immunology
Pandemics*
Pneumonia, Viral*/complications
Pneumonia, Viral*/immunology
Pneumonia, Viral*/pathology
Pneumonia, Viral*/physiopathology
Betacoronavirus/physiology ; Humans ; Immunity, Innate/drug effects ; Immunity, Innate/physiology ; Immunologic Factors/immunology ; Immunologic Factors/pharmacology ; Terminology as Topic
SCR Disease Name :
COVID-19
Raport
Tytuł :
Cytokine mRNA Degradation in Cardiomyocytes Restrains Sterile Inflammation in Pressure-Overloaded Hearts.
Autorzy :
Omiya S; The School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Omori Y; The School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Taneike M; The School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Murakawa T; The School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Ito J; The School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Tanada Y; The School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Nishida K; The School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Yamaguchi O; Department of Cardiovascular Medicine, Graduate School of Medicine (O.Y.), Osaka University, Suita, Japan.
Satoh T; Laboratory of Host Defense, Research Institute for Microbial Diseases (T.S., S.A.), Osaka University, Suita, Japan.
Shah AM; The School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Akira S; Laboratory of Host Defense, Research Institute for Microbial Diseases (T.S., S.A.), Osaka University, Suita, Japan.
Otsu K; The School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Pokaż więcej
Źródło :
Circulation [Circulation] 2020 Feb 25; Vol. 141 (8), pp. 667-677. Date of Electronic Publication: 2020 Jan 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Inflammation/*pathology
Interleukin-6/*metabolism
Myocytes, Cardiac/*metabolism
RNA, Messenger/*metabolism
Ribonucleases/*genetics
Animals ; Antibodies/immunology ; Antibodies/therapeutic use ; Cardiomyopathy, Dilated/etiology ; Cardiomyopathy, Dilated/metabolism ; Cardiomyopathy, Dilated/pathology ; Genetic Vectors/metabolism ; Heart Failure/etiology ; Heart Failure/prevention & control ; Inflammation/prevention & control ; Interleukin-6/genetics ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Receptors, Interleukin-6/immunology ; Ribonucleases/deficiency ; Ribonucleases/metabolism ; Up-Regulation
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies